HIGHLIGHTS
- who: Andrew Holden from the Auckland City Hospital, School of Medicine, University of Australia have published the research: Results from the First-in-Human Study of the Caterpillaru2122 Arterial Embolization System, in the Journal: (JOURNAL)
- what: This first-in-human trial was designed to assess occlusion success and adverse events associated with the use of the device. collected by the investigators using standardized webbased clinical report forms. The sample size was based on the potential adequacy of data to meet the study objectives, not statistical considerations. The CHRYSALIS trial was designed to assess the Caterpillar . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.